Chromium Sulphuricum

Chromic (Chromic Sulfate) is a trivalent chromium compound used primarily as a trace element supplement in parenteral nutrition to maintain glucose metabolism and prevent deficiency. It acts as a cofactor for insulin, enhancing its effectiveness at the cellular level.

The dosage of Chromic must be individualized based on the patient's metabolic requirements and clinical status. For stable adults receiving Total Parenteral Nutrition (TPN), the standard recommended dose of trivalent chromium is 10 to 15 mcg per day.

In patients with active chromium deficiency (characterized by glucose intolerance and high insulin requirements), a healthcare provider may temporarily increase the dose to 20 mcg per day until the metabolic state stabilizes. It is critical to note that these doses are for intravenous administration; oral doses of chromium (often found in over-the-counter supplements) are significantly higher (200-1000 mcg) due to poor intestinal absorption.

Chromic is approved for use in pediatric patients receiving TPN, but the dosage is strictly weight-based to prevent toxicity.

• Infants and Children: The recommended dose is 0.14 to 0.2 mcg/kg per day.
• Preterm Neonates: Special care must be taken as renal function is immature. Dosing usually starts at the lower end of the pediatric range and is closely monitored by a neonatologist.

> Warning: Excessive administration to infants can lead to accumulation and potential toxicity. Always follow the specific calculations provided by the neonatal intensive care unit (NICU) staff.

Renal Impairment

Chromic is primarily excreted by the kidneys. In patients with moderate to severe renal impairment (Stage 3-5 Chronic Kidney Disease), the dose must be significantly reduced or withheld. Healthcare providers typically monitor serum chromium levels and renal function (creatinine clearance) to avoid toxic accumulation. Accumulation in renal failure can lead to nephrotoxicity, creating a dangerous feedback loop.

Hepatic Impairment

While chromium is stored in the liver, it is not metabolized there. No specific dose adjustments are generally required for patients with isolated hepatic impairment, though global nutritional status should be monitored.

Elderly Patients

Geriatric patients often have a natural decline in glomerular filtration rate (GFR). Therefore, dosing should be conservative, starting at the lower end of the adult range (10 mcg/day), with frequent monitoring of kidney function.

Chromic Sulfate is not intended for direct injection. It must be prepared and administered as follows:

1. 1Dilution: The concentrated Chromic solution must be added to a large volume of TPN solution (usually 1 to 3 liters) under aseptic conditions in a pharmacy.
2. 2Administration: The TPN solution containing Chromic is administered via a central venous catheter or, in some cases, a peripheral IV line, using an infusion pump to ensure a constant rate.
3. 3Storage: Vials should be stored at room temperature (20°C to 25°C). Once added to a TPN bag, the solution is typically stable for 24 hours under refrigeration.

In the context of TPN, a 'missed dose' usually means the infusion was interrupted. If the TPN pump stops or the bag runs out, contact your healthcare provider immediately. Do not attempt to 'double up' the infusion rate to catch up, as this can cause fluctuations in blood sugar levels and potential electrolyte imbalances.

Chromic overdose is rare but serious. Signs of acute toxicity include:

• Severe nausea and vomiting
• Gastrointestinal hemorrhage
• Acute renal failure (decreased urine output)
• Liver damage (yellowing of the skin or eyes)
• Convulsions or coma in extreme cases

In the event of a suspected overdose, the infusion must be stopped immediately. Treatment is supportive and may involve hemodialysis to remove excess chromium from the blood. If you suspect an overdose, call 911 or your local emergency services immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or the rate of your TPN infusion without medical guidance.

Because Chromic is an essential trace element administered in microgram quantities, side effects are rare when dosed correctly. However, in the context of TPN administration, some patients may experience:

• Injection Site Reactions: Redness, swelling, or 'phlebitis' (inflammation of the vein) at the site of the IV insertion. This often feels like a warm, tender area along the vein.
• Changes in Blood Glucose: As Chromic improves insulin sensitivity, some patients may experience mild hypoglycemia (low blood sugar) if their insulin dose is not adjusted accordingly. Symptoms include shakiness, sweating, and lightheadedness.

• Gastrointestinal Distress: Mild nausea or abdominal cramping, although this is more common with oral chromium than IV Chromic Sulfate.

Chromic is a potent trace mineral that must only be administered under the supervision of a healthcare professional experienced in parenteral nutrition. The most critical safety factor is the balance between preventing deficiency and avoiding toxicity. Patients must undergo regular blood testing to ensure that the levels of chromium and other electrolytes remain within a safe therapeutic window.

As of 2026, there are no FDA black box warnings for Chromic (Chromic Sulfate). However, it is subject to the standard 'Parenteral Aluminum Warning' for all IV nutritional products. This warning highlights that the product may contain aluminum that could be toxic to premature neonates and patients with renal impairment.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to other metals (like nickel or cobalt) may have a higher risk of cross-sensitivity to chromium. If you have ever had a reaction to jewelry or metal fasteners, inform your doctor.

There are no medications that are strictly contraindicated with Chromic Sulfate in a way that prohibits use entirely; however, its use is contraindicated in patients with known hypersensitivity to chromium.

• Insulin and Sulfonylureas: Chromic significantly enhances the pharmacological effect of insulin and insulin secretagogues (like glipizide or glyburide). The clinical consequence is a high risk of severe hypoglycemia. Management: Healthcare providers must monitor blood glucose closely and proactively reduce the dose of diabetes medications when starting Chromic.
• Corticosteroids (e.g., Prednisone): Steroids typically cause hyperglycemia (high blood sugar) and can antagonize the glucose-lowering effects of chromium. Management: Patients on both may require higher doses of insulin despite the chromium supplementation.

Chromic (Chromic Sulfate) must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: Patients who have had an anaphylactic reaction or severe systemic dermatitis in response to chromium or any component of the injection (such as sulfates) must not receive this medication. The mechanism is an IgE-mediated or delayed-type T-cell hypersensitivity.
2. 2Severe Renal Failure (Anuric): In patients who are not producing urine and are not on dialysis, Chromic is absolutely contraindicated. Because the kidneys are the only significant exit route for chromium, administration would lead to rapid, life-threatening systemic toxicity.

Conditions requiring a careful risk-benefit analysis by a physician include:

Chromic is classified as FDA Pregnancy Category C. This means that adequate animal reproduction studies have not been conducted, and it is not known whether Chromic can cause fetal harm when administered to a pregnant woman.

• Risk-Benefit: Trivalent chromium is an essential nutrient, and deficiency during pregnancy can lead to gestational diabetes and poor fetal growth. Therefore, if a pregnant woman requires TPN, Chromic is typically included at standard doses.
• Monitoring: Close monitoring of blood glucose is required, as insulin requirements change rapidly during the second and third trimesters.

Chromium is naturally present in human breast milk. When administered at the recommended TPN doses, it is unlikely that Chromic Sulfate will significantly increase the concentration of chromium in milk beyond physiological levels. No adverse effects have been reported in nursing infants whose mothers were receiving TPN. However, caution is advised, and the infant should be monitored for normal growth and development.

Chromic (trivalent chromium) is an essential mineral that acts as a physiological enhancer of insulin activity. The specific molecular mechanism involves the formation of a complex with a peptide called chromodulin. When insulin binds to the extracellular alpha-subunit of the insulin receptor, it triggers the autophosphorylation of the intracellular beta-subunit.

Chromodulin, in its chromium-saturated state, binds to this activated receptor, stabilizing its 'active' conformation and increasing the activity of the tyrosine kinase enzyme by up to 8-fold. This results in an amplified signal for the translocation of glucose transporter proteins (GLUT4) from the cytoplasm to the cell membrane, facilitating the entry of glucose into the cell. Additionally, Chromic inhibits the enzyme phosphotyrosine phosphatase, which normally turns off the insulin receptor, thereby prolonging the insulin signal.

The pharmacodynamic effect of Chromic is measured by its ability to lower blood glucose and reduce the amount of exogenous insulin required by a patient. The onset of action is not immediate; in patients with a deficiency, it may take 3 to 7 days of continuous supplementation to see a stabilization in glucose levels. The duration of effect is long, as chromium is stored in tissues and slowly released.